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Zellweger spectrum disorders are a group of autosomal recessive disorders characterized by impaired peroxisome
functions. The clinical spectrum is broad, ranging from the classical most severe Zellweger syndrome to patients
with a relatively mild phenotype. Treatment options are limited to symptomatic and supportive therapy. During
routine follow-up we discovered patients with asymptomatic primary adrenal insufficiency. It is important to detect
impaired adrenal function because it has treatment implications. Primary adrenal insufficiency was found in 7/24
patients examined, with 4/7 being asymptomatic. Systematic evaluation of adrenal function, through a Synacthen
test, should be included in the clinical management of these patients.
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Peroxisomal disorders are a group of genetic disorders
with impairment in one or more peroxisomal functions
[1]. The peroxisomal disorders are divided into two major
categories: (1) the peroxisome biogenesis disorders with
multiple metabolic abnormalities (e.g. Zellweger spectrum
disorders (ZSDs), OMIM #601539), and (2) the disorders
with a deficiency of a single peroxisomal enzyme or
transporter (e.g. X-linked adrenoleukodystrophy (X-ALD),
OMIM #300100). X-ALD is characterized by accumula-
tion of very long-chain fatty acids (VLCFA, ≥C22:0), due
to an impaired peroxisomal beta-oxidation. Adrenal insuf-
ficiency, either subclinical or overt as well as the late onset
form, is found in the majority of X-ALD patients, and fre-
quently precede the neurological symptoms giving rise to
the “Addison-only” phenotype [2].
Adrenal insufficiency may also occur in ZSD patients.
The ZSDs are autosomal recessive disorders, characterized
by impairment of multiple peroxisomal functions due to
mutations in different PEX genes [1]. Clinically, the ZSDs
constitute a spectrum of disease severity, ranging from
severe (Zellweger syndrome (ZS), OMIM #214100) to at-
tenuated phenotypes, like infantile Refsum disease (IRD,* Correspondence: b.t.pollthe@amc.uva.nl
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unless otherwise stated.OMIM #266510) [3]. Most ZSD patients have disorders in
the milder end of the spectrum and should be follow-up
for symptomatic and supportive therapy. Among others,
these patients have elevated concentrations of VLCFA
and bile acid intermediates in plasma.
During routine follow-up we discovered impaired adre-
nocortical function in some of our ZSD patients. Because
most of the patients have severe neurological symptoms,
primary adrenal insufficiency might be easily overlooked.
Untreated adrenocortical dysfunction may have serious
consequences, while treatment is available [4]. To estimate
the prevalence of adrenocortical dysfunction and, with
that, to determine whether or not routine testing in these
patients is useful, we assessed the adrenal function in our
patients with a ZSD.Findings
The characteristics of the patients are presented in Table 1.
Twenty-four patients with a ZSD, age ranging from 2.8-
34.6 years (median 15.4 years) underwent a Synacthen test
(Additional file 1). An inadequate increase in plasma corti-
sol concentrations was found in 7/24 (29%) patients and
an adequate response in cortisol (>550 nmol/l) was seen
in the others. Four of the 7 patients (57%) diagnosed with
primary adrenal insufficiency, were asymptomatic. The 3
patients with clinical manifestations of adrenal insuffi-
ciency presented with muscle and/or joint pain, vomitingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






















(0.45-1.32) (0.45-1.32); STD (1–55) (>550) (0–7.5)
Adrenal insuf.
1 6.6 5.9 10.28 7.75; 1.57 100 203 / 275 / 290 asymp 5.5 ++ ++ PEX1 c.2528G > A
2 4.4 2.8 7 6.28; 1.13 180 201 / 254 / 260 asymp 5.5 ─ ─ PEX1 c.2528G > A
3 20.4 18.5 4.63 5.45; 2.47 # 112 / 273 / 306 asymp 5.1 ─ ─ PEX1 c.2528G > A/
c.2097insT
4 8.4 3.0 4.43 4.93; 0.99 # 200 / 260 / 190 v >576 ─ + PEX1 c.2528G > A
5 14.5 12.2 3.38 3.87; 1.37 5140 185 / 203 / 167 hp 4.9 ─ ++ PEX1 c.2528G > A
6 24.7 22.9 2.73 2.90; 0.78 66 156 / 203 / 202 hp, mp 2.7 ++ ─ PEX26 c.292C > T
7 11.8 10.1 2.28 2.40; 0.34 390 535 / 477 / 524 asym 6.3 + ++ PEX1 c.2528G > A
8 24.3 24.2 2.44 4.91; 3.98 53 428 / 734 / 781 + ─ PEX1 c.2528G > A
9 24.2 23.8 2.79 4.13; 1.10 44 441 / 624 / 624 + ─ PEX1 c.2528G > A/
unknown
10 6.8 5.8 3.38 3.94; 1.06 nd 370 / nd / 990 ─ ─ PEX1 c.2528G > A
11 10.3 9.1 3.78 3.94; 1.15 17 125 / 458 / 607 ─ ─ PEX1 c.2528G > A/
c.2097insT
12 8.7 8.2 3.21 3.77; 0.69 35 85 / 425 / 557 ++ ++ PEX1 c.2528G > A
13 29.8 29.4 3.7 3.71; 0.78 27 902 / 1079 / 1090 ++ + PEX1 c.2528G > A/
unknown
14 22.8 22.2 3.51 2.69; 1.28 26 306 / 629 / 701 ++ ++ PEX1 c.2528G > A
15 17.3 16.9 2.35 2.45; 0.46 20 270 / 601 / 698 ++ ++ PEX1 c.2528G > A
16 35.0 34.6 3.31 2.17; 0.67 9 342 / 624 / 648 ++ ++ PEX1 c.2528G > A
17 19.0 18.6 1.63 1.82; 0.46 25 430 / 668 / 778 ++ ++ PEX1 c.2528G > A
18 8.1 7.5 1.24 1.78; 0.18 44 571 / 726 / 690 ++ ++ PEX1 c.2528G > A
19 11.8 11.2 1.2 1.53; 0.35 33 189 / 601 / 687 ++ ++ PEX1 c.2528G > A
20 8.3 7.6 0.81 1.50; 0.74 34 588 / 910 / 993 ++ ++ PEX10 c. 1A > G/
c.199C > T
21 29.7 29.3 1.38 1.38; ** nd 215 / 620 / 705 ++ ++ PEX11β c.64C > T
22 15.4 14.6 1.8 1.38; 0.27 18 227 / 519 / 618 ++ ++ PEX26 c.292C > T
23 30.3 29.9 1.98 1.35; 0.39 19 274 / 579 / 709 ++ ++ PEX1 c.2528G > A
24 16.7 16.1 1.28 1.34; 0.34 17 356 / 593 / 665 ++ ++ PEX1 c.2528G > A
Asym = asymptomatic; hp = hyper pigmentation; mp =muscle pain; nd = not determined; STD = standard deviation, v = vomiting. ACTH in ng/l, cortisol in nmol/l, C26:0 in μmol/l, renin in ugA1/L/U.
The reference intervals are indicated between brackets and all results outside the intervals are depicted in bold.
* = average concentration of C26:0 in plasma during life, ranging from 1 analysis to 43 (median 12) analyses per patient, ** = only one C26:0 measurement, # = unreliable measurement, i.e. loss of ACTH
immunoreactivity caused by hemolysis. Phenotype: - = no communication or wheelchair bound, + = non-verbal communication or walk with support, ++ = verbal communication or independent walking. 1 = PEX



















Figure 1 Boxplots showing median, range and interquartile range of the VLCFA concentrations in plasma of the patients with or
without a primary adrenal insufficiency. (A) Mean of all VLCFA concentrations in time per patient (B) VLCFA concentrations around time of
ACTH stimulation test. Statistical analyses were performed with a Mann–Whitney U test.
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with additional adrenocortical dysfunction (i.e. hyperkale-
mia) as a sign of hypoaldosteronism [5]. Plasma renin was
normal in 6/7 patients. Oral hydrocortisone (and fludro-
cortisone in patient 4) treatment was started in all diag-
nosed patients.
To obtain a framework for comparing severity of the
clinical phenotype and adrenal insufficiency we delineated
three categories on the basis of the degree of communica-
tion and motor function (Table 1). Elevated plasma VLCFA
(C26:0) concentrations were present in 22/24, with an ab-
normal C26:0/C22:0 ratio in 24/24. Baseline plasma corti-
sol concentrations ranged from 85–902 nmol/l (median
272 nmol/l) and baseline plasma ACTH concentrations
from 9–390 ng/l (median 33 ng/l), with one patient having
5140 ng/l.
We found a correlation between the average concen-
trations of C26:0 and C26:0 levels around the time of
the ACTH test in plasma and the occurrence of an ad-
renal insufficiency (Figure 1). There was no correlation
between age, sex, PEX mutation or phenotypic severity
and adrenal dysfunction.
Discussion
In 1984, Govaerts et al. reported the occurrence of pri-
mary adrenal insufficiency in a small series of severe ZS
patients [6]. The prevalence in ZSD patients with atten-
uated phenotypes has not yet been investigated. In this
study we found a high prevalence of primary adrenal in-
sufficiency in a cohort of ZSD patients.
The pathophysiological mechanism underlying the pri-
mary (usually only glucocorticoid) adrenocortical dysfunc-
tion in ZSDs and X-ALD is unknown. Several studies,
including studies on post mortem material, suggest that
elevated (i.e. toxic) concentrations of VLCFA cause ad-
renal cell dysfunction leading to decreased cortisol re-
sponse and thus adrenal insufficiency [7-13]. We found a
correlation between the occurrence of an adrenal insuffi-
ciency and the concentration of C26:0 in plasma. Becauseplasma C26:0 concentrations can fluctuate over time due
to for instance diet, we used the average of all C26:0 values
over time for each patient (Figure 1). We observed no
adrenal insufficiency when the average concentration of
C26:0 in plasma was below 2.40 μmol/l, while all patients
with an average C26:0 > 4.91 μmol/l had adrenocortical
dysfunction (Table 1, n = 4). Due to the single time point
data, small size of our cohort and large variation in age,
the importance of the correlation between VLCFA con-
centrations in plasma and adrenal insufficiency should not
be overrated and needs confirmation in future studies.
In this study we found a high prevalence (29%) of pri-
mary adrenal dysfunction in ZSD patients, with some
being asymptomatic at the time of the test. We therefore
recommend that all ZSD patients should be screened for
adrenal insufficiency during routine follow-up, in order
to initiate appropriate therapy (Additional file 2).
Additional files
Additional file 1: Supplementary methods.
Additional file 2: Recommendations on the management of
primary adrenal insufficiency.
Abbreviations
IRD: Infantile Refsum disease; VLCFA: Very long chain fatty acids; X-ALD:
X-linked adrenoleukodystrophy; ZS: Zellweger syndrome; ZSD: Zellweger
spectrum disorder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KB, ME, BTPT: Conception and design, data acquisition, analysis, and
interpretation, manuscript draft and revision. GEL: Data acquisition,
interpretation, manuscript draft and revision. ASPvT: Design, interpretation,
manuscript draft and revision. All authors read and approved the final
manuscript.
Acknowledgments
The authors thank the patients and their families for their cooperation and
the referring physicians, especially Prof. B.H.R. Wolffenbuttel (University
Medical Centre Groningen, The Netherlands); Dr. M.E.J. Wegdam-den Boer
(Medical Spectrum Enschede, The Netherlands); Drs. A.B.C. Roeleveld-Versteegh
Berendse et al. Orphanet Journal of Rare Diseases 2014, 9:133 Page 4 of 4
http://www.ojrd.com/content/9/1/133(Catharina Hospital Eindhoven, The Netherlands) and Drs. I. N. Snoeck-Streef
(Haga Hospital The Hague, The Netherlands) for providing data of their patients.
We thank Dr. F. Vaz and Dr. H.R. Waterham (Academic Medical Centre,
The Netherlands) for providing biochemical and genetic data. This work is
supported financially by the Foundations “Stichting Steun Emma” and
“Metakids”, Amsterdam, The Netherlands.
Author details
1Department of Paediatric Neurology, Emma Children’s Hospital/Academic
Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands.
2Laboratory for Genetic Metabolic Diseases, Emma Children’s Hospital/
Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The
Netherlands. 3Department of Endocrinology and Metabolism, Emma
Children’s Hospital/Academic Medical Centre, Meibergdreef 9, Amsterdam
1105 AZ, The Netherlands. 4Department of Paediatric Endocrinology, Emma
Children’s Hospital/Academic Medical Centre, Meibergdreef 9, Amsterdam
1105 AZ, The Netherlands.
Received: 26 June 2014 Accepted: 18 August 2014
Published: 2 September 2014
References
1. Waterham HR, Ebberink MS: Genetics and molecular basis of human
peroxisome biogenesis disorders. Biochim Biophys Acta 2012, 1822:1430–1441.
2. Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJA, Aubourg P,
Poll-The BT: X-linked adrenoleukodystrophy (X-ALD): clinical presentation
and guidelines for diagnosis, follow-up and management. Orphanet J
Rare Dis 2012, 7:51.
3. Goldfischer S, Moore CL, Johnson AB, Spiro AJ, Valsamis MP, Wisniewski HK,
Ritch RH, Norton WT, Rapin I, Gartner LM: Peroxisomal and Mitochondrial
Defects in the Cerebro-Hepato-Renal Syndrome. Science 1973, 182:62–64.
4. Arlt W, Allolio B: Adrenal insufficiency. Lancet 2003, 361:1881–1893.
5. Marik PE: Mechanisms and clinical consequences of critical illness
associated adrenal insufficiency. Curr Opin Crit Care 2007, 13:363–369.
6. Govaerts L, Monnens L, Melis T, Trijbels F: Disturbed adrenocortical
function in cerebro-hepato-renal syndrome of Zellweger. Eur J Pediatr
1984, 143:10–12.
7. Govaerts L, Sippell WG, Monnens L: Further analysis of the disturbed
adrenocortical function in the cerebro-hepato-renal syndrome of
Zellweger. J Inherit Metab Dis 1989, 12:423–428.
8. Powers JM, Schaumburg HH, Johnson AB, Raine CS: A correlative study of
the adrenal cortex in adreno-leukodystrophy–evidence for a fatal
intoxication with very long chain saturated fatty acids. Invest Cell Pathol
1980, 3:353–376.
9. Knazek RA, Rizzo WB, Schulman JD, Dave JR: Membrane microviscosity is
increased in the erythrocytes of patients with adrenoleukodystrophy
and adrenomyeloneuropathy. J Clin Invest 1983, 72:245–248.
10. Whitcomb RW, Linehan WM, Knazek RA: Effects of long-chain, saturated fatty
acids on membrane microviscosity and adrenocorticotropin responsiveness
of human adrenocortical cells in vitro. J Clin Invest 1988, 81:185–188.
11. Van Den Branden C, Collumbien R, Roels F, Dacremont G, Roels H: Altered
Adrenocortical Response under the Influence of Experimentally
Increased Serum Very Long Chain Fatty Acids in Rats. Pathol Res Pract
1993, 189:558–562.
12. Goldfischer S, Powers JM, Johnson AB, Axe S, Brown FR, Moser HW: Striated
adrenocortical cells in cerebro-hepato-renal (Zellweger) syndrome.
Virchows Arch A Pathol Anat Histopathol 1983, 401:355–361.
13. Powers JM, Schaumburg HH: Adreno-leukodystrophy (sex-linked Schilder’s
disease). A pathogenetic hypothesis based on ultrastructural lesions in
adrenal cortex, peripheral nerve and testis. Am J Pathol 1974, 76:481–491.
doi:10.1186/s13023-014-0133-5
Cite this article as: Berendse et al.: High prevalence of primary adrenal
insufficiency in Zellweger spectrum disorders. Orphanet Journal of Rare
Diseases 2014 9:133.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
